Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
University of California
mi
from
San Diego, CA
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
University of California
mi
from
San Diego, CA
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Stanford Hospital and Clinics
mi
from
Stanford, CA
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Stanford Hospital and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
University of Florida College of Medicine (Shands)
mi
from
Gainesville, FL
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
University of Florida College of Medicine (Shands)
mi
from
Gainesville, FL
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
The Johns Hopkins SKCCC
mi
from
Baltimore, MD
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
The Johns Hopkins SKCCC
mi
from
Baltimore, MD
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
DFCI/Brigham & Women's Hospital
mi
from
Boston, MA
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
DFCI/Brigham & Women's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Duke University Medical Center (peds)
mi
from
Durham, NC
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Duke University Medical Center (peds)
mi
from
Durham, NC
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
University Hospitals of Cleveland/Case Western
mi
from
Cleveland, OH
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
University Hospitals of Cleveland/Case Western
mi
from
Cleveland, OH
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Oregon Health and Sciences University
mi
from
Portland, OR
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
University of Texas, MD Anderson CRC
mi
from
Houston, TX
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
University of Texas, MD Anderson CRC
mi
from
Houston, TX
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Texas Transplant Institute
mi
from
San Antonio, TX
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Texas Transplant Institute
mi
from
San Antonio, TX
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Washington University/ Barnes-Jewish Hospital
mi
from
Saint Louis, MO
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Washington University/ Barnes-Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
City of Hope Samaritan
mi
from
Phoenix, AZ
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
City of Hope Samaritan
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
City of Hope National Medical Center
mi
from
Duarte, CA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Scripps Clinic/Green Hospital
mi
from
La Jolla, CA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Scripps Clinic/Green Hospital
mi
from
La Jolla, CA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
UCSD Medical Center
mi
from
La Jolla, CA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
UCSD Medical Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Stanford Hospital and Clinics
mi
from
Stanford, CA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Stanford Hospital and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Colorado Blood Cancer Institute
mi
from
Denver, CO
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Colorado Blood Cancer Institute
mi
from
Denver, CO
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
University of Florida College of Medicine (Shands)
mi
from
Gainesville, FL
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
University of Florida College of Medicine (Shands)
mi
from
Gainesville, FL
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Emory University
mi
from
Atlanta, GA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
BMT Group of Georgia (Northside Hospital)
mi
from
Atlanta, GA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
BMT Group of Georgia (Northside Hospital)
mi
from
Atlanta, GA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Loyola University
mi
from
Maywood, IL
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Loyola University
mi
from
Maywood, IL
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
IBMT (Indiana Blood and Marrow Transplant) at St Francis Franciscan Health
mi
from
Indianapolis, IN
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
IBMT (Indiana Blood and Marrow Transplant) at St Francis Franciscan Health
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Wichita CCOP
mi
from
Wichita, KA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Wichita CCOP
mi
from
Wichita, KA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Tufts - New England Medical Center
mi
from
Boston, MA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Tufts - New England Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
DFCI/Brigham & Women's
mi
from
Boston, MA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
DFCI/Brigham & Women's
mi
from
Boston, MA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Jewish Hospital BMT Program
mi
from
Cincinnati, OH
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Jewish Hospital BMT Program
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
University Hospitals of Cleveland/Case Western
mi
from
Cleveland, OH
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
University Hospitals of Cleveland/Case Western
mi
from
Cleveland, OH
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
University of Oklahoma Medical Center
mi
from
Oklahoma City, OK
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
University of Oklahoma Medical Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Oregon Health Sciences University (A)
mi
from
Portland, OR
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Oregon Health Sciences University (A)
mi
from
Portland, OR
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Fox Chase, Temple University BMT Program
mi
from
Philadelphia, PA
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Fox Chase, Temple University BMT Program
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Vanderbilt University
mi
from
Nashville, TN
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Baylor College of Medicine/The Methodist Hospital
mi
from
Houston, TX
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Baylor College of Medicine/The Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
University of Texas MD Anderson Cancer Research Center
mi
from
Houston, TX
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
University of Texas MD Anderson Cancer Research Center
mi
from
Houston, TX
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Texas Transplant Institute
mi
from
San Antonio, TX
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Texas Transplant Institute
mi
from
San Antonio, TX
Click here to add this to my saved trials
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated:  8/24/2017
Utah BMT/University of Utah Medical School
mi
from
Salt Lake City, UT
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
Status: Enrolling
Updated: 8/24/2017
Utah BMT/University of Utah Medical School
mi
from
Salt Lake City, UT
Click here to add this to my saved trials